Allergenic Effect of Ambrosia in Israel
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01413256|
Recruitment Status : Unknown
Verified August 2011 by Rambam Health Care Campus.
Recruitment status was: Not yet recruiting
First Posted : August 10, 2011
Last Update Posted : August 10, 2011
Respiratory allergic reaction causes great suffering to millions of people worldwide. One of the most known allergen- is the pollen from vegetation, ragweed. Genus Ambrosia Ambrosia belonged to the complex ragweed flowers are pollinated by the wind and the plant's male flowers produce large quantities of small grains of pollen and airborne over long distances and those causes allergic reactions. The plant blooms between June and October, creating a second wave after wave of allergy caused by spring blossoms.
This plant originated in North America has invaded many areas in Europe and in recent years, taking over large areas in Israel, Hula Valley and northern Acre Emek Hefer for a pen and layers to the south. After ragweed plants are based in particular they spread quickly and invade agricultural fields and significantly reduce the crop.
High allergenic ragweed is a health hazard to humans. Ragweed plant investigated many aspects of North America and Europe in recent decades and extensive literature on ambrosia, but this is the first time ragweed study focuses on Israel.
Working hypothesis and aims:
Goal of this study is to identify the existence and nature of the sensitivity distribution of ragweed in Israel.
Importance of research:
A. Ragweed allergen testing and comparing the effect of exposure to plants on the sensitivity of the allergic Israeli patients
B. The inclusion of ragweed allergen in the diagnostic and therapeutic panel
|Condition or disease|
|Allergy Ambrosia Ragweed|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2012|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01413256
|Contact: Eduardo Shahar, PIemail@example.com|